Assessment of the incidence of venous thromboembolism in patients with Covid-19 admitted to an intensive care unit
Objective: To assess the incidence of venous thromboembolism (VTE) in patients hospitalized in an intensive care unit (ICU) due to Covid-19, its relationship with D-dimer levels and other possible associated factors. Method: A cross-sectional and retrospective study, carried out in a public university hospital, between April and June 2021. The sample consisted of patients ≥ 15 years old with positive reverse transcription polymerase chain reaction (RT-PCR) for Sars-CoV-2, excluding pregnant and postpartum women who had ICU admission. Data were collected and tabulated in the Microsoft Office Excel ® program and analyzed using the R Studio® software. Continuous variables were expressed as mean and standard deviation, and categorical variables were expressed as absolute (n) and relative (%) frequencies, and analyzed by Chi-square, a confidence level <0.05 was adopted. Results: The study consisted of 144 patients (61.1% male), with a mean length of stay in the ICU of 14.2±10.3 days. The incidence of deep vein thrombosis (DVT) in these patients was 19% and 5% for pulmonary thromboembolism (PTE). Regarding the D-dimer test, it was noted that the group with the presence of DVT+PTE had a higher median. In total, 31.2% patients were anticoagulated. There was a statistically significant relationship between the performance of hemodialysis and the clinical outcome of death (p<0.05). Conclusion: It is concluded that 21% of the evaluated patients had VTE during their stay in the ICU. The study contributed to characterizing the profile of patients with Covid-19 admitted to the ICU who developed VTE, with the purpose of presenting consistent data that will allow improving the planning of the health care process.
Wu C, Chen X, Cai Y, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–43. DOI: 10.1001/jamainternmed.2020.0994.
Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality among Patients with Hypertension Hospitalized with COVID-19. Circ Res. 2020;126(12):1671–81. DOI: 10.1161/CIRCRESAHA.120.317134.
Saghazadeh A, Rezaei N. Immune-epidemiological parameters of the novel coronavirus–a perspective. Expert Rev Clin Immunol [Internet]. 2020;16(5):465–70. DOI: 10.1080/1744666X.2020.1750954.
Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol. 2020;92(10):2105–13. DOI: 10.1002/jmv.25987.
Neves RA, Borges MA, de Lima Barros GE. (2022). Estado de coagulação em pacientes infectados pelo sars-cov-2: uma revisão sistemática. Revista EVS-Revista de Ciências Ambientais e Saúde, 48(1), 9047.
Tiburi RGB, Jucá MCP, Sales M de S, et al. Coagulopatia induzida pelo estado inflamatório da infecção pela Covid-19 / Coagulopathy induced by the inflammatory state of Covid infection 19. Brazilian J Heal Rev. 2021;4(2):8478–501. DOI: 10.34119/bjhrv4n2-368.
Brito VP de, Dias FLT, Oliveira S. Hipertensão arterial sistêmica, uso de bloqueadores dos receptores de angiotensina II e inibidores da enzima conversora da angiotensina e COVID-19: Uma revisão sistemática. Interam J Med Heal. 2020;3:3–6. DOI: 10.31005/iajmh.v3i0.120.
Crawford F, Andras A, Welch K, et al. D-dimer test for excluding the diagnosis of pulmonary embolism. Cochrane Database Syst Rev. 2016;2016(8). DOI: 10.1002/14651858. CD010864.pub2.
Rezende SM. Disturbios da Hemostasia: doenças hemorrágicas. Rev Med Minas Gerais. 2010;20(4):534–53.
Ramanathan K, Antognini D, Combes A, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(January):497–506.
Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ. 2020;368. DOI: 10.1136/bmj.m1091.
Pancani R, Villari L, Foci V, et al. Lower limb deep vein thrombosis in COVID-19 patients admitted to intermediate care respiratory units. Thromb Res. 2021;197(January):44–7. DOI: 10.1016/j.thromres.2020.10.035.
Lax SF, Skok K, Zechner P, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: Results from a prospective, single-center, clinicopathologic case Series. Ann Intern Med. 2020 Sep 1;173(5):350–61. DOI: 10.7326/M20-2566.
Medcalf RL, Keragala CB, Myles PS. Fibrinolysis and COVID-19: A plasmin paradox. J Thromb Haemost. 2020 Sep 1;18(9):2118–22. DOI: 10.1111/jth.14960.
Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicentre prospective cohort study. Intensive Care Med [Internet]. 2020;46(6):1089–98. DOI: 10.1007/s00134-020-06062-x.
Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120–8. DOI: 10.1056/nejmoa2015432.
Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavírus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–9. DOI: 10.1111/jth.14817.
Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141. DOI: 10.1378/chest.11-2296.
Argenta C, Beltrami L. Análise de custo-minimização do uso de heparina não-fracionada e enoxaparina em uma coorte de pacientes em tratamento de tromboembolismo venoso [dissertação]. Porto Alegre: Universidade Federal do Rio Grande do Sul; 2007.
Flaczyk A, Rosovsky RP, Reed CT, et al.. Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: Implications for clinical practice and future investigations. Crit Care. 2020;24(1):1–13. DOI: 10.1186/s13054-020-03273-y.
How to Cite
Copyright (c) 2022 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.